Compare Stocks: RDY, ONC, RPRX, and ZTS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ONC BeOne Medicines	$350.84	$344.32	$253.95 ▼ $385.22	$38.52B	0.51	336,490 shs	438,376 shs
RDY Dr. Reddy's Laboratories	$12.19 +0.0%	$12.13	$11.36 ▼ $15.67	$10.18B	0.28	2.58 million shs	1.89 million shs
RPRX Royalty Pharma	$58.41	$59.45	$34.63 ▼ $64.38	$33.59B	0.44	3.06 million shs	7.10 million shs
ZTS Zoetis	$71.53 +0.2%	$75.31	$71.00 ▼ $148.79	$29.56B	0.73	4.55 million shs	9.87 million shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ONC BeOne Medicines	0.00%	+1.25%	-6.31%	+29.08%	+4.92%
RDY Dr. Reddy's Laboratories	0.00%	+2.41%	+0.02%	-12.37%	-17.95%
RPRX Royalty Pharma	0.00%	-0.34%	-4.73%	+9.03%	+61.18%
ZTS Zoetis	0.00%	-2.08%	-7.96%	-5.74%	-50.95%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ONC BeOne Medicines	$350.84	$344.32	$253.95 ▼ $385.22	$38.52B	0.51	336,490 shs	438,376 shs
RDY Dr. Reddy's Laboratories	$12.19 +0.0%	$12.13	$11.36 ▼ $15.67	$10.18B	0.28	2.58 million shs	1.89 million shs
RPRX Royalty Pharma	$58.41	$59.45	$34.63 ▼ $64.38	$33.59B	0.44	3.06 million shs	7.10 million shs
ZTS Zoetis	$71.53 +0.2%	$75.31	$71.00 ▼ $148.79	$29.56B	0.73	4.55 million shs	9.87 million shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ONC BeOne Medicines	0.00%	+1.25%	-6.31%	+29.08%	+4.92%
RDY Dr. Reddy's Laboratories	0.00%	+2.41%	+0.02%	-12.37%	-17.95%
RPRX Royalty Pharma	0.00%	-0.34%	-4.73%	+9.03%	+61.18%
ZTS Zoetis	0.00%	-2.08%	-7.96%	-5.74%	-50.95%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ONC BeOne Medicines	3.00	Buy	$402.71	14.79% Upside
RDY Dr. Reddy's Laboratories	1.50	Reduce	N/A	N/A
RPRX Royalty Pharma	3.00	Buy	$61.29	4.92% Upside
ZTS Zoetis	2.32	Hold	$101.08	41.30% Upside

Current Analyst Ratings Breakdown

Latest RDY, ONC, RPRX, and ZTS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/14/2026	RPRX Royalty Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
9/10/2026	ONC BeOne Medicines	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$407.00 ➝ $415.00
9/9/2026	ZTS Zoetis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
9/8/2026	RPRX Royalty Pharma	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$65.00 ➝ $68.00
8/25/2026	ZTS Zoetis	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$104.00 ➝ $94.00
8/25/2026	ZTS Zoetis	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$94.00
8/20/2026	ZTS Zoetis	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$85.00 ➝ $80.00
8/12/2026	RPRX Royalty Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy (B-)
8/11/2026	ZTS Zoetis	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$112.00 ➝ $96.00
8/11/2026	ZTS Zoetis	BNP Paribas Exane Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$146.00 ➝ $110.00
8/10/2026	ONC BeOne Medicines	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$370.00

(Data available from 9/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ONC BeOne Medicines	$6.13B	6.28	$3.91 per share	89.76	$39.77 per share	8.82
RDY Dr. Reddy's Laboratories	$3.58B	2.84	$0.85 per share	14.39	$4.86 per share	2.51
RPRX Royalty Pharma	$2.54B	13.24	$4.78 per share	12.23	$16.83 per share	3.47
ZTS Zoetis	$9.53B	3.10	$7.58 per share	9.44	$7.56 per share	9.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ONC BeOne Medicines	$286.93M	$5.68	61.77	25.74	N/A	10.70%	14.23%	7.82%	N/A
RDY Dr. Reddy's Laboratories	$456M	$0.44	27.71	21.39	2.54	10.15%	9.49%	6.32%	10/23/2026 (Estimated)
RPRX Royalty Pharma	$770.95M	$1.45	40.28	10.56	1.38	32.14%	30.01%	14.91%	11/4/2026 (Estimated)
ZTS Zoetis	$2.67B	$6.07	11.78	11.30	1.67	27.49%	74.89%	18.59%	11/3/2026 (Estimated)

Latest RDY, ONC, RPRX, and ZTS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	ZTS Zoetis	$1.85	$1.87	+$0.02	$1.65	$2.50 billion	$2.47 billion
8/5/2026	Q2 2026	ONC BeOne Medicines	$1.40	$2.05	+$0.65	$2.05	$1.66 billion	$1.71 billion
8/5/2026	Q2 2026	RPRX Royalty Pharma	$1.27	$1.32	+$0.05	$0.04	$758.93 million	$674.14 million
7/23/2026	Q1 26/27	RDY Dr. Reddy's Laboratories	$0.0918	$0.06	-$0.0318	$0.06	$850.56 million	$850.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ONC BeOne Medicines	N/A	N/A	N/A	N/A	N/A
RDY Dr. Reddy's Laboratories	$0.06	0.49%	+6.96%	13.64%	N/A
RPRX Royalty Pharma	$0.94	1.61%	+24.01%	64.83%	5 Years
ZTS Zoetis	$2.12	2.96%	+20.11%	34.93%	14 Years

Latest RDY, ONC, RPRX, and ZTS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/17/2026	RPRX Royalty Pharma	quarterly	$0.2350	1.6%	8/14/2026	8/14/2026	9/10/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ONC BeOne Medicines	0.17	3.40	3.06
RDY Dr. Reddy's Laboratories	0.03	1.90	1.39
RPRX Royalty Pharma	0.88	2.80	2.80
ZTS Zoetis	2.87	3.08	1.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ONC BeOne Medicines	48.55%
RDY Dr. Reddy's Laboratories	3.85%
RPRX Royalty Pharma	54.35%
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
ONC BeOne Medicines	6.19%
RDY Dr. Reddy's Laboratories	2.00%
RPRX Royalty Pharma	18.84%
ZTS Zoetis	0.22%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ONC BeOne Medicines	12,000	109.79 million	102.99 million	N/A
RDY Dr. Reddy's Laboratories	27,527	834.67 million	817.98 million	Optionable
RPRX Royalty Pharma	100	575.00 million	466.67 million	Optionable
ZTS Zoetis	14,500	413.22 million	412.32 million	Optionable

RDY, ONC, RPRX, and ZTS Headlines

Recent News About These Companies

Nykredit A S Buys New Position in Zoetis Inc. $ZTS

4 hours ago | marketbeat.com

Zoetis stock lags market as analysts brace for earnings decline

September 19 at 5:17 PM | ad-hoc-news.deA

Zoetis (ZTS) Stock Drops Despite Market Gains: Important Facts to Note

September 18 at 7:15 PM | zacks.com

10 large and mega-cap US healthcare stocks with the weakest momentum grades

September 18 at 11:14 AM | msn.com

Zoetis (ZTS) Stock Fair Value Falls After Mixed Analyst Cuts And Softer Growth Views

September 18 at 11:14 AM | finance.yahoo.com

Zoetis: The Worst May Be Priced In

September 18 at 10:30 AM | seekingalpha.com

Zoetis: The Worst May Be Priced In

September 18 at 10:14 AM | seekingalpha.com

Zoetis Stands by Guidance as Pet-Care Weakness and Competition Pressure Sales

September 18 at 1:01 AM | marketbeat.com

Zoetis: Companion Animal Weakness Keeps Me On The Sidelines

September 17, 2026 | seekingalpha.com

Zoetis: An Undervalued Compounder Hiding In Plain Sight

September 17, 2026 | seekingalpha.com

Zoetis: New Competition Changes The Story, But Not Yet The Rating

September 17, 2026 | seekingalpha.com

Allworth Financial LP Cuts Holdings in Zoetis Inc. $ZTS

September 15, 2026 | marketbeat.com

Zoetis Inc. (ZTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 14, 2026 | seekingalpha.com

Corient Private Wealth LP Has $35.07 Million Holdings in Zoetis Inc. $ZTS

September 14, 2026 | marketbeat.com

Zoetis Inc. $ZTS Shares Sold by Baird Financial Group Inc.

September 14, 2026 | marketbeat.com

Zoetis Inc. $ZTS Shares Sold by Capital Analysts LLC

September 14, 2026 | marketbeat.com

The Manufacturers Life Insurance Company Has $16.64 Million Position in Zoetis Inc. $ZTS

September 13, 2026 | marketbeat.com

National Pension Service Raises Stock Holdings in Zoetis Inc. $ZTS

September 12, 2026 | marketbeat.com

Zoetis Inc. $ZTS Shares Sold by Cidel Asset Management Inc.

September 12, 2026 | marketbeat.com

Engineers Gate Manager LP Increases Stock Position in Zoetis Inc. $ZTS

September 11, 2026 | marketbeat.com

Zoetis Inc. $ZTS Shares Sold by California State Teachers Retirement System

September 11, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RDY, ONC, RPRX, and ZTS Company Descriptions

BeOne Medicines NASDAQ:ONC

$350.84 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$360.83 +9.99 (+2.85%)

As of 07:34 AM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Dr. Reddy's Laboratories NYSE:RDY

$12.19 +0.00 (+0.02%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$12.24 +0.05 (+0.42%)

As of 07:10 AM Eastern

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Royalty Pharma NASDAQ:RPRX

$58.41 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$58.41 0.00 (0.00%)

As of 07:37 AM Eastern

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Zoetis NYSE:ZTS

$71.53 +0.13 (+0.18%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$71.85 +0.32 (+0.44%)

As of 07:38 AM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RDY, ONC, RPRX, and ZTS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RDY, ONC, RPRX, and ZTS Earnings

Compare Dividends

Latest RDY, ONC, RPRX, and ZTS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RDY, ONC, RPRX, and ZTS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RDY, ONC, RPRX, and ZTS Company Descriptions

BeOne Medicines NASDAQ:ONC

Dr. Reddy's Laboratories NYSE:RDY

Royalty Pharma NASDAQ:RPRX

Zoetis NYSE:ZTS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools